Navigation Links
Biomarkers: What can they tell us
Date:12/12/2008

SAN ANTONIO - As cancer researchers move away from the general use of chemotherapy and into more targeted approaches, scientists are working to discover effective ways to measure response and risk. Data presented at the CTRC-AACR San Antonio Breast Cancer Symposium illustrate the cutting edge of biomarker discovery and development.


Reductions in Breast Density Predict Potential Benefit of Tamoxifen
Abstract #61, Jack Cuzick, Ph.D.

A reduction in breast density of at least 10 percent may predict who benefits from the breast cancer preventive effects of tamoxifen. Researchers studied 1,063 women and found that those with reduced breast density after 12 to 18 months of treatment had a 52 percent reduced risk of breast cancer. By contrast, those women who did not have a decrease in breast density had only an eight percent risk reduction.

Full release available/Complete data to be presented at the meeting


Poor Prognosis on Small, HER2 Positive Tumors
Abstract #701, Ana M. Gonzalez-Angula, M.D

Although current guidelines call for no further therapy after surgery on breast tumors one centimeter or smaller, a new study suggests that if these tumors are HER2 positive patients have an increased risk for relapse. In the largest study of its kind to date (n=1,315, including a validation set), researchers found that the five-year recurrence rate was 23 percent among patients with small HER2-positive tumors, compared with eight percent in other tumor types.

Full release available/Complete data to be presented at the meeting


New Genetic Modeling Improves Screening
Abstract #502, Kathie Dalessandri, M.D.

A new genetic model based on 22 single nucleotide polymorphisms may improve the ability to predict risk of developing breast cancer. Researchers found that in a high-risk population from Marin County, California, this model improved diagnostic accuracy by 51 percent compared to classic risk factors alone.

Full release available/Complete data to be presented at the meeting.


New Biomarker Predicts Anthracycline Response
Abstract #45, John Bartlett, Ph.D.

The presence of chromosome 17 polysomy effectively predicted which patients would benefit from adjuvant anthracycline chemotherapy. Researchers analyzed 1,625 samples from NEAT (National Epirubicin Adjuvant Trial) and found that those patients with C17 polysomic tumors had significantly greater benefit from epirubicin than those without, even when taking HER2 status into consideration. Researchers suggest that this may explain the apparent association of anthracycline sensitivity and HER2 status which is located on this chromosome.

Complete data to be presented at the meeting.


Biomarkers May Not Identify Proper Chemotherapy Treatment
Abstract # 705, Angelo Di Leo, M.D., Ph.D.

Chemotherapy treatment selection based on biomarkers may not yet be a valuable practice. Prior studies have suggested that HER2 and topoisomerase II (TOP2A) might predict sensitivity to particular chemotherapy agents. An interim analysis shows that HER2 and TOP2A have a clinically modest and statistically borderline predictive value.

Full data to be presented at the meeting.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner Tal ... and no time to decompress, Rabinowitz found herself drawn to a casual meditation class ... impact on her life, implementing a 20-minute-per-day meditation practice with her team. After her ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, ... announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration ... business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... ... 12, 2016 , ... The Jones Agency, a family owned insurance company with ... a cooperative charity drive with the Tarrant Area Food Bank in the hopes of ... families in need, the Tarrant County Food Bank offers hope and security to the ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ procurement organization that ... partnership with San Ramon Regional Medical Center. Under the collaboration, the first of its ... to accommodate a more certain time frame for donor families for the recovery of ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Holdings, Inc. (NASDAQ: IPHS ), a leading international producer ... will host a live conference call on Tuesday, February 23, ... and full year 2015 results. --> ... and full year results will be issued on Monday, February ... --> The conference call can be accessed ...
(Date:2/12/2016)... , Feb. 12, 2016   HeartWare International, ... conference call and webcast to discuss its financial results ... 2015, on Thursday, February 25, 2016 at 8:00 a.m. ... prior to the conference call and webcast.  On the ... financial results, highlights from the fourth quarter and business ...
(Date:2/12/2016)...  Memorial Hermann Health System has teamed up with ... bring a one-of-a-kind experience to pediatric patients at ... as 360-degree video and Google Cardboard, Howard was able ... giving the patients and their families an unexpected, and ... on video . Memorial Hermann IRONMAN ...
Breaking Medicine Technology: